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Summary A previous study has shown that there are high levels of an abnormally-fucosylated form of
haptoglobin (FHp) in the blood of cancer patients (Thompson & Turner, 1987b). In this study, we investigated
the expression of this substance in serial blood specimens from women with ovarian or breast cancer who were
undergoing cytotoxic chemotherapy. The level of FHp was related to patient response to therapy status, this
latter index being an indirect determination of tumour burden. FHp levels did not correlate with gross liver
metastasis (as shown by CT scans or the blood levels of liver enzymes). This conclusion was further supported
by results from patients with hepatocellular cancer. FHp was elevated in most of these patients, but the
pattern of change did not correlate with variations in the level of the hepatoma marker, alpha-foetoprotein. It
seems likely that FHp is produced by the liver. Primary and secondary tumours could release substances, such
as cytokines, which interfere with fucose metabolism in the liver.
We have previously reported that cancer sera have high levels
of an abnormal form of haptoglobin (FHp) that can be
extracted from blood using the fucose-specific lectin Lotus
tetragonolobus (Thompson & Turner, 1987a). The expression
of this molecule is related to the amount of protein-bound
fucose in the blood, but is not related to the total hapto-
globin concentration (Thompson & Turner, 1987b). The
same molecule was not present in the blood from healthy
individuals or in individuals with inflammatory diseases such
as rheumatoid arthritis (Thompson & Turner, 1987b) or
bronchial pneumonia (Thompson & Turner, 1988) despite the
haptoglobin levels in these diseases being frequently elevated.
Additional studies of 11 serial specimens from two ovarian
cancer patients showed that elevated levels of FHp were
associated with increasing tumour burden (Thompson et
al.,1987b). In order to confirm and extend these observations
we have further investigated FHp by measuring its level in
150 serial specimens from 21 women with ovarian cancer and
27 women with breast cancer. As the cause of the changes in
the fucosylation of haptoglobin is unknown, we have ex-
plored the possibility that elevated FHp levels result from the
presence of metastatic deposits in the liver.
Materials and methods
Patients
Blood specimens were obtained by venepuncture from 21
women with ovarian cancer (median age = 60 yr; range
33-79); from 27 women with breast cancer (median
age = 60 yr; range 40-77); and from nine women and seven
men with hepatocellular cancer. Sera were separated by low
speed centrifugation for 10 min and were stored at - 20°C.
All analyses were carried out within 2 years of collection.
Ovarian cancers were diagnosed by laparotomy (stages
III/IV) and confirmed by histology (serous or mucinous
adenocarcinoma). At laparotomy, different amounts of
tumour were removed; in all cases tumour remained in the
abdomen, despite attempts at total surgical debulking, but
for some patients this was a very small amount. During the
period of specimen collection, 17 patients received several
courses of Carboplatin chemotherapy, one patient received
several courses of Cisplatin, one patient received several
courses of Chlorambucil, one patient received several courses
of Mitoxanthrone and another patient received several
courses of Treopsulphan. Some patients had had therapy
with Cisplatin prior to receiving Carboplatin.
The 27 women who had breast cancer had undergone
either a lumpectomy or a mastectomy 6 months to 20 years
previously (median 3.5 yr). Twenty-four women still had
clinical signs of cancer when specimen collection was started.
During the period of collection the major therapies were as
follows: Mitoxanthrone (ten women); aminoglutethimide,
hydrocortisone, disodium pamidronate (three); amino-
glutethimide, hydrocortisone (three); Tamoxifen (two);
Cyclophosphamide, 5-fluoruracil, prednisolone (two); Ifos-
phamide, Doxorubicin (one); Vincristine, prednisolone (one);
Vincristine, mitomycin (one); LHRH agonist (one); radio-
therapy (one) and two were untreated. Nineteen of the
women were previously treated with radiotherapy; 17 of these
received Tamoxifen and five had prior treatment with Mitox-
anthrone.
At least two blood specimens were collected from each
ovarian and breast cancer patient (median number three;
range two to six) over a period of time that varied (median
time = 12 months; range 1-22 months). The time between
collections also varied (median = 3 months; range 1- 15
months). Seventy-seven and 73 specimens were collected from
the ovarian and breast patients respectively. Only one or two
specimens were collected from the hepatoma patients.
Ovarian and breast cancer patients were assessed when
specimens were collected; these assessments were made by
clinical examination and appropriate radiological and ultra-
sound scanning techniques. The patient response to therapy
was categorised into three groups; complete response, partial
response or stable disease, and progressive disease. Complete
response was defined as complete disappearance of all
demonstrable disease for at least 4 weeks. Partial response
was defined as a reduction (> 50% bidimensional or > 30%
unidimensional) in total size of measurable disease, and
stable disease was defined as < 50% change (bidimensional)
or <30% (unidimensional) in the total size of the
measurable lesions. Progressive disease was defined as a
>50% (bidimensional) or >30% (unidimensional) increase
in the size of any measurable lesion.
The hepatocellular cancers were diagnosed by physical
examination combined with radiological and ultrasonic scan-
ning techniques, and confirmed by the histological examina-
tion of biopsy material. No information was available for the
clinical assessments of the hepatoma patients.
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Identification ofSerum FHp
These methods have been extensively described elsewhere
(Thompson & Turner, 1987a,b; Thompson et al., 1987).
Briefly, a fucose-binding lectin (Lotus tetragonolobus, Sigma)
was coupled to CNBr-activated Sepharose beads (Pharmacia)
at 2mgml-' beads. Fucoproteins were extracted from 751 l
aliquots of serum by mixing with 75jil lotus lectin-beads for
1.5 h at 25°C. Unbound proteins were removed by six washes
0.05 mol 1-' Tris-HCl, pH 7.4, containing 25 mmol 1' KCl,
5 mmol -1 CaCl2, 5 mmol 1' MgCl2 and 0.5% (v/v) Nonidet
P40. In preliminary experiments, bound fucoproteins were
eluted from the beads either by incubating for 30 min with
50pl of the Tris washing buffer containing 1.0 mol 1' fucose
or by solubilising in 50jil of 125 mmol 1-i Tris-HCI, pH 6.8,
containing 0.35 mol l-1' sodium dodecyl sulphate (SDS),
2.7 mol l-' glycerol, 1 mmol l' EDTA and 2.9 mmol l-
bromophenol blue. Eluted material was reduced by boiling
for 5 min in 5% (v/v) P-mercaptoethanol, and the denatured
fucoproteins (12 Al extract) were separated in 8% (w/v)
polyacrylamide slab gels using the discontinuous Laemmli
buffer system. A silver staining procedure (Thompson, 1987)
was used to visualise the separated proteins and the FHp
band was identified by its molecular weight. For some speci-
mens, the identity of this component was further confirmed
by Western blotting (Thompson & Turner, 1987b). Any
specimen that was haemolysed was not analysed for FHp.
Comparisons of the electrophorectic patterns of serum fuco-
proteins extracted by either fucose of SDS are given in
Figure 1. Patterns are also shown for sera that were extracted
with Sepharose beads alone. It can be seen that both fucose
and SDS extract a molecule that migrates at 40-45 kDaltons
(subsequently identified as the P-chain of haptoglobin by
Western blotting). This band is only seen if the specimen is
extracted with Sepharose beads coupled to lotus lectin. As the
SDS procedure usually removed larger amounts of the
40-45 kDalton component, this method was routinely em-
ployed for extraction of fucosylated haptoglobin from the
cancer sera.
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Figure 1 Silver-stained electrophoretic separations of two pools
of sera collected from patients with progressive breast or ovarian
cancer. Groups 1 and 2 are the pooled sera extracted with two
batches of Sepharose beads and eluted with SDS. Groups 3 and 4
are lotus-lectin-Sepharose extracts of the ovarian and breast
pool respectively. In groups 3 and 4 the left-hand lane was eluted
with fucose and the right-hand lane with SDS. In Figures 1-4;
12JlI were loaded for each specimen (- 1.25;Lg protein); the
position of the molecular weight markers (phosphorylase B,
94 kDa; serum albumin, 68 kDa; catalase, 60 kDa; ovalbumin,
45 kDa and aldolase, 40 kDa) are shown on the left-hand side of
the patterns by horizontal lines; the position of the FHp band is
shown on the right-hand side of the patterns by an arrow-head.
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Figure 2 Silver-stained electrophoretic separations of lotus-extracted sera from eight women with ovarian cancer. All women were
undergoing cytotoxic chemotherapy. Groups 1-3 are from women who showed a complete response to therapy; groups 4-6 are
from women who had stable disease followed by progressive disease; and groups 7 and 8 from women who had progressive disease.
The sharp bands at 40-45 kDa in groups 1-3 were shown by Western-blotting not to be Hp. The time interval between the first
and last samples for each patient was 148, 203, 278, 266, 348, 226, 154 and 34 days respectively.
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Other tests andmeasurements
Aspartate aminotransferase (AST), alkaline
(AP) and billirubin (BR) were measured on ser
during routine diagnostic investigations o
Chemispec Autoanalyser using the manufactu
mended procedures. The upper limits for referen
AST, AP and BR were 37 Uml-', 130 U ml-' an
respectively. Serum alpha-foetoprotein (AFP)
measured during routine investigations using A
(Abbott Laboratories, UK). The AFP conceni
expressed in jg 1' using the International
Research on Cancer (IARC) AFP reference ma
as the standard. The upper limit of the referen
10fg 1'. Data was analysed statistically using
Results
Figures 2 and 3 show representative electrophoi
obtained after the separation of Lotus-extracte(
teins from 14 cancer patients (eight ovarian an
The results from the analysis of two to four s
shown for each patient. Some of the patients ar
to cytotoxic chemotherapy (groups 1-3, Figur
whereas other patients are not responding to
have an increasing tumour burden (groups 4-
groups 4-6, Figure 3). It can be seen that
association between the intensity of a diffusely-s
at 40-45 KDa and increasing involvement of tk
breast cancer.
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The 40-45 kDa band was shown to be the P-chain of
phosphatase haptoglobin by subjecting the electrophoretically-separated
am specimens extracts to the Western-blotting procedure using an anti-
n a Hilger haptoglobin antibody. Figure 4 shows representative results
irers' recom- of this type of analysis for four patients who are not re-
ice ranges for sponding to therapy. Specimens from three patients are the
id 170 U ml-' same as those used in Figure 2 and the other group of
t levels were specimens is from a patient used in Figure 3. It can be seen
sFP EIA kits that the antibody detects a diffuse band at 40-45 kDa that
trations were increases in intensity with increasing tumour involvement,
Agency for and that these changes in antibody staining reflect those
terial 72/225 observed for the 40-45 kDa bands observed on the silver- ace range was stained patterns. The lotus-extracted haptoglobin will subse-
the x2 test. quently be referred to as FHp. The sharp minor bands seen between 40 and 45 kDa on the silver-stained patterns, parti-
cularly in groups 1-3 Figure 2, did not blot for haptoglobin.
Table I summarises the results of FHp determinations on
all the serial specimens collected from 21 ovarian and 27
retic patterns breast cancer patients. The data are presented as semi-
d serum pro- quantitative estimations of the intensity of staining of the
d six breast). FHp band asjudged by two independent investigators. These ,pecimens are assessments are grouped according to the patient response at
*e responding the time when the specimen was collected i.e., 'complete
*es 2 and 3); response'; 'partial response or stable disease'; or 'progressive
therapy and disease'. It can be seen that for both cancers, there is a highly
-8, Figure 2 significant association between the amount ofFHp present in
t'here is an the blood and increasing tumour burden. In one ovarian tamring band patient (four specimens) and three breast patients (three te ovarian or specimens) FHp was undetectable even when they had pro-
gressive disease.
Twenty-six cancer patients (14 ovarian and 12 breast) were
assessed for the presence of liver metastases using computed
tomographic (CT) scans. Metastases could not be detected in
15 patients; whereas a moderate or strongly staining FHp
was detectea in blooa specimens trom 13 of these patients.
Metastases were detected in the remaining 11, but only eight
of these had a moderate or strongly staining FHp band.
Statistical analysis of this data showed that there was no
significant correlation between the presence of liver meta-
stases and the amount of FHp in the blood (P>0.05, x2
test). In other studies, aspartate aminotransferase (AST)
activity was measured in 91 specimens from 35 cancer
patients (20 ovarian and 15 breast). Increased activity of this
enzyme frequently indicates liver damage (Whitby et al.,
1984). AST was elevated above the normal reference range
(>37 U m-') in only 11 of the specimens; whereas 54 speci-
mens had a moderate or strongly-stained FHp band. Statis-
tical analyses indicated that there was no correlation between
the AST and FHp levels in the ovarian group (P>0.05, x2
test_ anti a vt-rv winlr neend-intinn hattivnasr fkaoa +--,- L%,atj-ajLjV a v 1i w a& uJbmaLLion LJeLween Lines two
measurements in the breast group (P = 0.03, x2 test). Two
other indicators of liver function (alkaline phosphatase and
6 bilirubin) were also measured in many of the blood speci-
_ .. __ mens. Again, no significant correlation was observed between
1 2 3 4
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Figure 3 Silver-stained electrophoretic separation'
extracted sera from six women with breast cancer.
were undergoing cytotoxic chemotherapy. Groups 1-
women who had stable disease and/or complete remis'
4-6 are from women who had progressive disease
interval between the first and last samples for each
126, 220, 572, 112, 384 and 440 days respectively.
s of lotus-
All women Figure 4 A Western blot (anti-haptoglobin) ofcancer sera lectin-
-3 are from extracts separated by electrophoresis. Groups 1 to 3 are the same
sion; groups specimens as shown in groups 4 to 6 of Figure 2 respectively,
e. The time except that only the first two specimens from group 5 are shown
patient was in this figure. Group 4 are the first three specimens from group 5,
Figure 3.
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Table I Relationship between serum FHp levels and the response of
21 ovarian and 27 breast cancer patients to chemotherapy
FHp assessment
(No. of specimens)
Not present Moderate Strong
Patient group or weak band band band
Ovarian cancer
Complete response 22 5 0
Partial response or 12 9 1
stable disease
Progressive disease 4 8 16
Breast cancer
Complete response 9 3 0
Partial response or 14 20 6
stable disease
Progressive disease 3 9 9
The association between FHp assessment and patient response to
therapy is highly significant (ovarian, P <0.0001; breast, P = 0.002).
The X2 test was carried out by pooling the data for the 'Moderate
Band' and 'Strong Band' groups.
the levels of these substances and the amount of FHp pres-
ent.
FHp levels and alpha-fetoprotein concentrations were
determined in 23 specimens from 16 patients with hepatocel-
lular cancer. Five specimens had a weak band or no band,
two of these being > 1,000 ig I-; 12 specimens had a
moderate band, eight of these being > 1,000 g1%'; and six
specimens had a strong band, two ofthese being > 1,000pg 1-'.
Statistical analysis of this data indicated that there was no
significant correlation between the levels of these two sub-
stances (P >0.05, x2 test).
Discussion
This investigation has shown that there is an abnormally-
fucosylated form of haptoglobin (FHp) in the blood of
women with ovarian or breast cancer. This finding confirms
the results from a previous preliminary study of 22 patients
with different advanced cancers that included three women
with breast cancer and three women with ovarian cancer
(Thompson & Turner, 1987b). The 48 women evaluated in
the present study were monitored for up to 22 months whilst
receiving cytotoxic or hormone therapy. The intensity of the
FHp band was found to increase with increasing disease
involvement, and if a patient had no evidence of disease, i.e.
'a complete response', then either the FHp band was not
detected or it was very weakly expressed. This pattern was
consistent for 44 out of 48 of the patients studied. Four
patients did not show an increase in FHp with progressive
disease; a possible explanation for this will be discussed
below. Although there was considerable variation in the
therapeutic regime used from patient to patient, this variable
did not seem to affect FHp levels.
As the liver is the major source ofhaptoglobin in the body
(Koj, 1974) and as malignant tumours frequently metastasise
to this organ (Weiss, 1985), it seemed possible that the FHp
arose through the increasing presence of metastatic tumour
in the liver that was affecting the fucosylation of hapto-
globin. However, results from our study did not support this
concept. There was a surprising lack of association between
FHp expression and the presence of liver metastases on CT
scans, and the elevation of serum enzymes that reflect liver
damage. It is important to mention, however, that these
latter methods only detect the presence of gross metastasis.
They do not exclude the possibility that micrometastases
were present, which were playing an important role in the
production of FHp.
The effect of the tumour growing in the liver on the
formation of FHp was further investigated by measuring the
levels of FHp and AFP in the same specimens from indivi-
duals with primary hepatomas. AFP is a good marker for
hepatomas, and blood levels are related approximately to
tumour burden (Bates & Longo, 1987). There was no correla-
tion between the levels of these two substances. In fact, in
some patients who had high amounts of FHp the AFP level
was low, and in other patients with high AFP the FHp levels
were only moderately elevated. The most likely explanation is
that as hepatomas grow and replace normal liver tissue, the
ability of the liver to form FHp is reduced. This possibility is
interesting because it suggests that only normal liver tissue
can form abnormally fucosylated haptoglobin. It may explain
why no strong relationship was detected between FHp levels
and the presence of gross metastases as detected by the CT
scans and the liver enzyme measurements. Also, three of the
four patients who did not show an increase in FHp with
progressive disease, had evidence of extensive liver metastasis
at the start of specimen collection.
A possible source of FHp could be the tumour itself.
Yoshimura et al. (1978) have shown that haptoglobin can be
detected in the blood plasma of nude mice bearing a trans-
planted human renal cell carcinoma. Furthermore, a recent
study (Kuhadja et al., 1989) has detected a protein in invas-
ive breast carcinomas that is related to haptoglobin (Hpr).
The HPR gene locus is a stretch of DNA located 2.2
kilobases downstream from the conventional HP locus
(Maeda, 1985; Bensi et al., 1985). The HPR sequence codes
for a protein whose a and P chains are distinct from, but
highly homologous to haptoglobin 1-1. A major difference in
the HPR sequence is the presence of a retrovirus-like ele-
ment. One of the minor changes is the substitution of a
histidine residue for a serine residue close to one of the
glycosylation sites. As this change will switch-off the
glycosylation at this site, Hpr will have only three potential
sites of glycosylation compared with the normal four (Nils-
son et al., 1981). Therefore, the lectin-binding properties of
Hpr and Hp will probably be different, but whether FHp and
Hpr are related is still unclear. In preliminary experiments,
however, we have been unable to detect haptoglobin or FHp
in cultured human cancer cell lines or in the media from
these lines (unpublished observations).
A more likely source of FHp is the liver. The tumour may
release soluble factors which promote the addition of fucose
to haptoglobin in the liver. Recent evidence was suggested
that cancer cells can produce factors (e.g. IL6) that can affect
the glycosylation of acute phase proteins in the liver
(Mackiewicz et al., 1989). As the factors could be secreted by
tumour that was growing at the primary site, in the liver or
in another secondary site, it might be expected that the
production of FHp would be related to overall tumour
burden. Thic conclusion agrees with our current findings.
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